Appendix A: Implementation Timelines

Goal 1: Identify needs to protect Americans against current and emerging threats

Objective	Description	Timeline
Objective 1.1	Conduct regular threat horizon scans to better prepare for CBRN and EID threats, as well as novel and emerging and public health threats, and integrate the full range of solutions (including Non-Pharmaceutical Interventions) into MCM preparedness and response plans	Within 273 days of SIP approval
Objective 1.2	Integrate threat characterization and risk analysis information into MCM portfolio considerations including an assessment of tradeoffs and future development pathways	Within 273 days of SIP approval
Objective 1.3	Develop portfolio optimization strategies that include an evaluation of development challenges and opportunities as well as end user needs	Within 365 days of SIP approval
Objective 1.4	Implement all of the above into a capabilities-based requirements process and utilization framework	Within 365 days of SIP approval

Objective	Description	Timeline
Objective 2.1	Engage with established advisory committees, senior leader councils, SLTT authorities, and non-governmental organizations (domestic and international) to identify the challenges within the MCM enterprise	Within 180 days of SIP approval
Objective 2.2	Establish a plan for rapid identification of MCM gaps that prioritizes and coordinates expedited advanced R&D to close those gaps during emerging pandemics, and rapidly assess safety and efficacy of novel MCMs	Within 365 days of SIP approval
Objective 2.3	Outline short-, medium-, and long-term R&D priorities for the end-to-end MCM development cycle and adjust based on strategic environment and threat assessment	Within 365 days of SIP approval
Objective 2.4	Establish Feedback mechanisms with PHEMCE partners to ensure two-way communication on addressing gaps and shortfalls	Within 120 days of SIP approval

Objective	Description	Timeline
Objective 3.1	Outline recommendations and progress made in a comprehensive portfolio that meets declared MCM priorities, including MCMs that address at-risk population and pediatric needs, to project SNS stockpiling and replenishment	Within 550 days of SIP approval
Objective 3.2	Evaluate progress of all development activities: R&D, procurement, stockpiling, deployment, distribution, and utilization; using an evaluation system based on performance management best practices--including progress made in meeting timelines, allocations, benchmarks, and milestones	Within 60 days of completing Objective 3.1
Objective 3.3	Outline short-, medium-, and long-term R&D priorities for the end-to-end MCM development cycle and adjust based on strategic environment and threat assessment	Within 365 days of SIP approval
Objective 3.4	Regularly assess and communicate priorities in a transparent and deliberative fashion	Ongoing